Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 826 - 850 of 1348 in total

Adalimumab

Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered ... arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. ... [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Biologics for Rheumatoid Arthritis Treatment …
Matched Products: … IDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL ... IDACIO solution for Injection for paediatric use 40mg/0.8ml ... HUMIRA SOLUTION FOR INJECTION …

Sulfamethizole

A sulfathiazole antibacterial agent.
Approved
Investigational
Vet approved
Matched International brands: … Thiosulfil Forte …
Matched Mixtures name: … OTTOPRIM FORTE ... OTTOPRIM FORTE …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use ... Blood and Blood Forming Organs ... Sulfonamides and trimethoprim ... Blood Substitutes and Perfusion Solutions …
Matched Products: … S*ORIPOL FORTE®. ... S*ORIPOL FORTE - SULFAMETIZOL 500 MG CAPSULAS …

Rituximab

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , [FDA label]. It was originally...
Approved
Matched Description: … sequences and human constant region sequences [A40017], [FDA label]. ... to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for ... The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Biologics for Rheumatoid Arthritis Treatment ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … Mabthera Concentrate for Solution for Infusion 100mg/10ml ... TRUXIMA® CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML ... MABTHERA CONCENTRATE FOR SOLUTION FOR INFUSION 500 mg/50ml …

Nivolumab

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb. Nivolumab was...
Approved
Matched Description: … with the mutation _S228P_ for additional stability and reduced variability. ... [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region …
Matched Categories: … Amino Acids, Peptides, and Proteins ... nivolumab and relatlimab ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … OPDIVO CONCENTRATE FOR SOLUTION FOR INFUSION 10 MG/ML ... NIVOLUMAB BMS CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML ... Opdivo 10mg/ml, Concentrate for solution for infusion …

Acazicolcept

Investigational
Matched Synonyms: … cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Sodium zirconium cyclosilicate

Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval...
Approved
Investigational
Matched Description: … [L2933] It is administered orally and is odorless, tasteless, and stable at room temperature. ... [L2933] The treatment effect was maintained for up to 12 months.[L2933] ... Approval of the medication is supported by data from three double-blind, placebo-controlled trials and …
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia ... Potassium Binder ... Potassium-removing Agents …
Matched Products: … LOKELMA POWDER FOR ORAL SUSPENSION 5G ... LOKELMA POWDER FOR ORAL SUSPENSION 10G ... Lokelma 5g Powder for Oral Suspension …

Denosumab

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for ... fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men ... [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs for Treatment of Bone Diseases ... Drugs Affecting Bone Structure and Mineralization …
Matched Products: … XGEVA 120mg Solution for Injection ... XGEVA Solution for Injection 120 mg/vial ... Prolia Solution for Injection 60mg Pre-filled Syringe …

Cimetidine

A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Approved
Investigational
Matched Description: … It inhibits gastric acid secretion, as well as pepsin and gastrins output. ... It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant …
Matched Categories: … Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) ... Alimentary Tract and Metabolism ... Metabolic Side Effects of Drugs and Substances ... Drugs for Acid Related Disorders …
Matched Products: … Up and Up Acid Reducer …

Isavuconazole

Isavuconazole is an triazole antifungal with broad spectrum of activity and good safety profile . It is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. It works by inhibiting fungal cell membrane synthesis. Invasive fungal infections pose significant clinical challenges for patients, especially those...
Approved
Investigational
Matched Description: … It is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. ... Isavuconazonium displays excellent water solubility for intravenous formulations, good absorption, and ... Cresemba for the treatment of invasive aspergillosis and mucormycosis as oral or intravenous administration …
Matched Categories: … Isavuconazole and Prodrugs ... Triazole and tetrazole derivatives ... Antimycotics for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … CRESEMBA (POWDER FOR SOLUTION FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 MG/VIAL) …

Etelcalcetide

Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Approved
Investigational
Matched Description: … Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism ( ... Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing …
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins …
Matched Products: … PARSABIV SOLUTION FOR INJECTION 5 mg/mL ... Parsabiv 5mg solution for injection ... PARSABIV SOLUTION FOR INJECTION 2.5 mg/0.5 mL …

Carfilzomib

Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Approved
Investigational
Matched Description: … Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. ... FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Products: … KYPROLIS POWDER FOR SOLUTION FOR INFUSION 60MG/VIAL ... KYPROLIS POWDER FOR SOLUTION FOR INFUSION 30 MG/VIAL ... Kyprolis (carfilzomib) powder for solution for infusion 60mg/vial …

Irinotecan

Irinotecan is a topoisomerase inhibitor used for chemotherapy. It is a water-soluble analogue of camptothecin, which is extracted from the Chinese tree Camptotheca acuminate. The bis-piperidine side chain in the structure of irinotecan bestows enhanced water solubility. As an anticancer drug, irinotecan was first commercially available in Japan in 1994...
Approved
Investigational
Matched Description: … Irinotecan is a topoisomerase inhibitor used for chemotherapy. ... Both irinotecan and SN-38 mediate antitumor activity by forming a complex with topoisomerase I and blocking ... This leads to the arrest of the cell cycle in the S-G2 phase and cancer cell death.[A263376] …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Products: … IRITEC CONCENTRATE FOR SOLUTION FOR INFUSION 40mg/2ml ... IRITEC CONCENTRATE FOR SOLUTION FOR INFUSION 100mg/5ml ... Irinotesin Concentrate for Solution for Infusion 20mg/ ml …

Zoledronic acid

Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid...
Approved
Matched Description: … [A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia ... third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and ... of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. …
Matched Categories: … Drugs for Treatment of Bone Diseases ... Drugs Affecting Bone Structure and Mineralization ... zoledronic acid, calcium and colecalciferol, sequential …
Matched Products: … ZOVA CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/5ML ... ZOLETEM CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/5ML ... ZOBONE CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/5ML …

Topotecan

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Approved
Investigational
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Products: … HYCAMTIN (POWDER FOR SOLUTION FOR INFUSION) ... TOCANTIN POWDER FOR SOLUTION FOR INFUSION 4MG ... TOCANTIN POWDER FOR SOLUTION FOR INFUSION 4 MG/VIAL …

Doxorubicin

Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed...
Approved
Investigational
Matched Synonyms: … MTC-DOX for Injection …
Matched Description: … Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers. ... [A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain ... [A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … DOXABIN POWDER FOR SOLUTION FOR INJECTION 10MG/VIAL ... DOXABIN POWDER FOR SOLUTION FOR INJECTION 50MG/VIAL ... DOXOCCORD CONCENTRATE FOR SOLUTION FOR INFUSION 2 MG/ML …

Ferric derisomaltose

Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. Though it is generally considered non...
Approved
Matched Description: … This drug is a complex of iron (III) hydroxide and derisomaltose. ... Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. ... is associated with other forms of injectable iron. …
Matched Products: … MONOFER® SOLUTION FOR INJECTION OR INFUSION 100 MG/ML ... Monofer 100 mg/ml solution for injection/infusion in vials ... Monofer 100mg/ml solution for injection/infusion in ampoules …

Canakinumab

Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy...
Approved
Investigational
Matched Description: … Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older ... part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and ... and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Products: … Ilaris Powder for Solution for Injection 150mg/vial ... ILARIS 150MG POWDER FOR SOLUTION FOR INJECTION …

Alirocumab

Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which...
Approved
Matched Description: … high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and ... FDA approval was contingent on the completion of further clinical trials to better determine efficacy and ... Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hypolipidemic Agents Indicated for Hyperlipidemia ... Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia …
Matched Products: … PRALUENT 150 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN) ... PRALUENT 75 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN) ... PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 75MG/ML …

Golimumab

Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with...
Approved
Matched Description: … Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients ... Golimumab binds and inhibits soluble and transmembrane human TNFα. ... Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Biologics for Rheumatoid Arthritis Treatment …
Matched Products: … Concentrate for Solution for Infusion 12.5mg/1 ml ... SIMPONI IV 12.5mg/1ml Concentrate for Solution for Infusion ... SIMPONI SOLUTION FOR INJECTION …

Insulin glulisine

Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by ... Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. ... Type 1 and Type 2 Diabetes. …
Matched Categories: … Insulins and Analogues for Injection, Fast-Acting ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … APIDRA 100 Units/ml Solution for Injection in vial ... APIDRA 100 U/ML- SOLUTION FOR INJECTION IN VIAL ... Apidra SoloStar 100 Units/ml Solution for injection in a pre-filled pen …

Guselkumab

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in...
Approved
Investigational
Matched Description: … In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological ... market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. ... Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …
Matched Products: … TREMFYA 100MG/ML SOLUTION FOR INJECTION ... Tremfya One-Press 100mg/ml Solution for Injection ... TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML …

Emicizumab

Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable...
Approved
Investigational
Matched Description: … Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017. ... Ltd. and co-developed with Roche and Genentech.[L1015] ... it has the capacity to bind simultaneously to activated Factor IX and Factor X. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Matched Products: … HEMLIBRA 30MG/ML SOLUTION FOR INJECTION ... HEMLIBRA 150MG/ML SOLUTION FOR INJECTION ... HEMLIBRA SOLUTION FOR INJECTION 30MG/ML …

Afoxolaner

Experimental
Vet approved
Matched Mixtures name: … Nexgard Spectra 38mg/8mg Chewable Tablets for Dogs >7.5-15kg ... Nexgard Spectra 9mg/2mg Chewable Tablets for Dogs 2-3.5kg ... Nexgard Spectra 19mg/4mg Chewable Tablets for Dogs >3.5-7.5kg …
Matched Products: … NexGard 11mg chewable tablets for dogs 2-4kg ... NexGard 136mg chewable tablets for dogs > 25-50kg ... NexGard 28mg chewable tablets for dog > 4-10kg …

Agalsidase alfa

Agalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Matched Products: … REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML …

Risankizumab

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab...
Approved
Investigational
Matched Description: … It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and ... [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. ... [L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716] …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …
Matched Products: … SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML ... SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.83ML ... SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML …
Displaying drugs 826 - 850 of 1348 in total